Drugs / BCG-Russia
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 4 | NCT04383925 Comparator | May 2020 → Oct 2022 | cardiomyopathy, infantile hypertrophic | Bandim Health Project | Completed | No outcome recorded |
| Phase 4 | NCT03400878 Comparator | Oct 2017 → Jun 2020 | — | Bandim Health Project | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCG-Russia | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03400878 ↗ |
| Known as | BCG-Russia-I | “Infants randomized to receive BCG-Russia at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine BCG-Russia-I (Serum...” NCT04383925 ↗ |
| Modality | Vaccine | “BCG-RUSSIA Infants randomised to receive BCG-RUSSIA at discharge from the Maternity Ward will receive one 0.05 ml dose Mycobacterium bovis BCG live attenuated vaccine” NCT03400878 ↗ |
| Route | Other | “by intradermal injection in the left deltoid region.” NCT03400878 ↗ |